Objective:

To evaluate the impact of digitalis glycosides on heart failure events and mortality in patients with heart failure with reduced or mildly reduced ejection fraction.

Key Findings:

Interpretation:

Digitalis glycosides may be beneficial in reducing worsening heart failure events but do not improve overall survival, suggesting a need for reevaluation of their role in contemporary heart failure management based on the findings of this meta-analysis.

Limitations:

Conclusion:

Digitalis glycosides are associated with a lower risk of worsening heart failure events but do not reduce mortality, indicating a potential role in heart failure management focused on event reduction rather than survival.